AtriCure stock
ATRCNASDAQAtriCure, Inc., HealthcareISIN US04963C2098
51Score 51 out of 100, Neutral
Price and trend
69 / 100
Price history
+69% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 44% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 15% below its 52-week high. Largest decline in 20 years: 92% (January 2008 to April 2009).
Chart figures for advanced users
- SMA 50$57.39
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$38.99
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$25.86
- The lowest closing price of the last twelve months.
- Resistance$65.53
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AtriCure, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $2.85B, is number 30 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $534.53M (up 14.9% year on year) and a loss of $11.45M.
- For fiscal 2026, analysts expect on average revenue of $607.14M (up 13.6%) and adjusted earnings per share of $0.11.
Show more
- MEQIRI Score 51 out of 100 (Neutral): rank 364 of 702 in Healthcare, median 53.
- The P/E is 187.4 (Medical (Instruments & Supplies) median 34.6, own median of recent years 62.6).
- Our model puts fair value at $16.61, with the price 237% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 389% of earnings over the last 12 months.
- Growing faster than its industryRevenue up 20.9% a year since 2020, Medical (Instruments & Supplies) median 9.5%.Growth 69
- More cash than debtCash $187.03M, financial debt $93.11M.Stability 60
Weaknesses
- Above fair valuePrice 237% above the fair value of $16.61.Valuation 10
- Richly valuedP/E 187.4, Medical (Instruments & Supplies) median 34.6, own median 62.6.Valuation 10
- DilutionShare count up 13% since 2020.Capital allocation 25
Its standout strength is momentum, while capital allocation and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 53 to 51.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $11.86 and expensive above $27.68 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $22.90 (cash-flow model) and $10.32 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $14.70, at 7.8% it would be $19.46.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 13.8% on the twelve months before. Revenue has grown strongly since 2006, at around 15% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 74%, operating −1%, net −2%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 16 Feb 2027in 95 days
- Last reported
- 3 Nov 2026EPS reported $0.17 (expected −$0.06)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 5.1% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.11−0.2%
- Revenue
- $607.14M+0.1%
- Earnings per share
- $0.40−5.1%
- Revenue
- $680.02M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +4.5%2026 guidance raised: revenue to $602 million to $610 million (up 12.5% to 14%) and adjusted EBITDA to $85 million to $89 million.
“And finally, turning to our outlook for 2026, we now expect to achieve $602 million to $610 million in revenue for the year, reflecting growth of approximately 12.5% to 14% over 2025.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 23 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 9 insiders sold, $4.23M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Johnson B KristineSale
6 Nov 2026, Board
- Shares
- 2,452
- Price
- $58.48
- Value
- $143,393
- Privitera SalvatoreSale
4 Nov 2026, Chief Technical Officer
- Shares
- 8,404
- Price
- $65.00
- Value
- $546,260
- Privitera SalvatoreSale
23 Sept 2026, Chief Technical Officer
- Shares
- 4,519
- Price
- $60.00
- Value
- $271,140
Show 11 more
- Groves Regina ESale
11 Sept 2026, Board
- Shares
- 5,313
- Price
- $54.22
- Value
- $288,071
- Privitera SalvatoreSale
8 Sept 2026, Chief Technical Officer
- Shares
- 3,657
- Price
- $55.00
- Value
- $201,135
- Privitera SalvatoreSale
2 Sept 2026, Chief Technical Officer
- Shares
- 7,763
- Price
- $52.50
- Value
- $407,558
- Dahlquist Karl S.Sale
24 Aug 2026, Chief Legal Officer
- Shares
- 9,370
- Price
- $48.89
- Value
- $458,099
- Prange KarenSale
5 Aug 2026, Board
- Shares
- 3,564
- Price
- $38.80
- Value
- $138,283
- Yuen MaggieSale
5 Aug 2026, Board
- Shares
- 3,500
- Price
- $38.42
- Value
- $134,470
- Noznesky Justin JSale
29 Jul 2026, Chief Mktg & Strategy Officer
- Shares
- 6,182
- Price
- $38.80
- Value
- $239,862
- Doraiswamy VinayakSale
28 Jul 2026, Chief Scientific Officer
- Shares
- 6,000
- Price
- $38.88
- Value
- $233,280
- Wehrwein SvenSale
28 Jul 2026, Board
- Shares
- 25,000
- Price
- $37.84
- Value
- $946,000
- Prange KarenSale
20 May 2026, Board
- Shares
- 3,000
- Price
- $28.65
- Value
- $85,950
- Doraiswamy VinayakSale
15 May 2026, Chief Scientific Officer
- Shares
- 5,000
- Price
- $28.13
- Value
- $140,650
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at AtriCure
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 51
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Tecan GroupTECN.SW $3.9B52
- Pulse BiosciencesPLSE $3.84B46
- SCHOTT Pharma AG & Co. KGaA1SXP.F $3.63B70
- Carl Zeiss MeditecAFX.DE $3.34B64
- AddLifeALIF-B.ST $2.14B58
- Bonesupport HoldingBONEX.ST $2.07B72
- AzentaAZTA $1.92B50
- SKAN GroupSKAN.SW $1.87B72
ETFs that hold AtriCure
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.30% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.26% | 0.40% | €813.42M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.18% | 0.30% | €185.82M |
Show 5 more
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.16% | 0.30% | €2.31B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.10% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.10% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.09% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.05% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.